anti-tumor effect mediated the inhibition of regulatory T cell migration

• Project/Area Number: 25830117
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Tumor therapeutics
• Research Institution: Okayama University
• Principal Investigator: Eikawa Shingo 岡山大学, 医歯(薬)学総合研究科, 助教 (40635265)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Project Status: Completed (Fiscal Year 2015)
• Budget Amount: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000); Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
• Keywords: 制御性T細胞

Outline of Final Research Achievements

In this study, we investigated whether the regulation of Treg migration and accumulation into tumor tissues leads to reduce tumor growth using a peptide which blocks chemoattractants of IL-8. We previously reported rather high production of IL-8 in all tumors and IL-6 in one lung cancer, the malignant mesothelioma, and the malignant melanoma and observed enrichment of Foxp3+ CD4 Tregs in migrated T cells to both IL-6－ and IL-8－ producing tumors. Marked induction of CXCR1 expression on Foxp3+ CD4 Tregs by IL-6 followed by IL-8－mediated migration appeared to be responsible for enriched migration.